Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

Study summary

Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma. This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly. The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPaclitaxel and carboplatin

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 19, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?56 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Bristol-Myers Squibb
Interventions being studied: Drug: Paclitaxel and carboplatin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be histologically or cytologically confirmed.
No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers
No previous irradiation to the only area of measurable disease.

Reasons someone may not be able to joinExclusion criteria

Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years.
Patients who have undergone surgery less than 3 weeks prior to enrollment.
History of serious cardiac disease not adequately controlled.
Patients with serious active infections or other serious underlying medical condition.
Uncontrolled diabetes mellitis.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Genesis Cancer CenterHot Springs, Arkansas
Little Rock Hematology/Oncology AssociatesLittle Rock, Arkansas
Highlands Oncology GroupSpringdale, Arkansas
Medical Oncology Care AssociatesOrange, California
Naval Medical CenterSan Diego, California
Danbury Hospital/Praxair Cancer CenterDanbury, Connecticut
Walter Reed Army HospitalWashington D.C., District of Columbia
Washington VA Medical CenterWashington D.C., District of Columbia
Good Samaritan Medical CenterWest Palm Beach, Florida
Wellstar Cobb HospitalAustell, Georgia
Joliet Oncology/Hematology Associates,Ltd.Joliet, Illinois
Mid Illinois Hematology and Oncology Associates, Ltd.Normal, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 19, 2016. Always confirm current availability with the study team.

View original record ↗